Selinexor (NCT05985161)

Name: Selinexor trial for Wilms Tumor (NCT05985161)
Uploaded: 2026-10-31T21:56:39.974Z
Duration: 1 min 24 s
Description: Selinexor trial for Wilms Tumor (NCT05985161). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05985161.

A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors: a one-minute explainerNCT059851611 min

Selinexor trial for Wilms Tumor (NCT05985161). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for patients with qualifying relapsed/refractory Wilms tumor, treatment-resistant rhabdoid tumor or MPNST, BCOR-activated sarcoma, or other solid tumors with supporting biological evidence. Access below age six depends on pharmacokinetic cohort status.

The idea: weekly liquid selinexor blocks XPO1, keeping tumor-suppressing proteins inside the cell nucleus. Researchers measure tumor response.

This phase 2 study plans 45 patients. Michael Ortiz leads at Memorial Sloan Kettering in New York. Sixteen US locations are marked recruiting, including limited-activity and data-only sites. Prior XPO1 inhibitors are excluded.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.